UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000006405 |
|---|---|
| Receipt number | R000007600 |
| Scientific Title | Randomized Double Blind Study to Evaluate the Efficacy of Droperidol Added to Patient-Controlled Epidural Analgesia with fentanyl for Prevention of Post-Operative Nausea and Vomiting in Subjects Undergoing Gynecologic Surgery |
| Date of disclosure of the study information | 2011/10/07 |
| Last modified on | 2014/08/22 15:23:52 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Randomized Double Blind Study to Evaluate the Efficacy of Droperidol Added to Patient-Controlled Epidural Analgesia with fentanyl for Prevention of Post-Operative Nausea and Vomiting in Subjects Undergoing Gynecologic Surgery
Acronym
Randomized Double Blind Study to Evaluate the Efficacy of Droperidol Added to Patient-Controlled Epidural Analgesia with fentanyl for Prevention of Post-Operative Nausea and Vomiting in Subjects Undergoing Gynecologic Surgery
Scientific Title
Randomized Double Blind Study to Evaluate the Efficacy of Droperidol Added to Patient-Controlled Epidural Analgesia with fentanyl for Prevention of Post-Operative Nausea and Vomiting in Subjects Undergoing Gynecologic Surgery
Scientific Title:Acronym
Randomized Double Blind Study to Evaluate the Efficacy of Droperidol Added to Patient-Controlled Epidural Analgesia with fentanyl for Prevention of Post-Operative Nausea and Vomiting in Subjects Undergoing Gynecologic Surgery
Region
| Japan |
Condition
Condition
Condition is enough to require surgery under combined general-epidural anesthesia, for example myoma of the uterus, ovarian cyst, denomyosis of the uterus, uterine corpus cancer, uterine cervical cancer, and cancer of ovary et al.
Classification by specialty
| Obstetrics and Gynecology | Anesthesiology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
The purpose of this study is to determine if subjects who receive droperidol added to patient-controlled epidural analgesia (PCEA) with fentanyl plus intravenous (IV) droperidol have less post-operative nausea and vomiting (PONV) than those who receive PCEA without droperidol plus IV droperidol only.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
Incidence of postoperative nausea and vomiting at each assessment point
Complete responder: No vomiting and use of rescue medications within 3 postoperative days
Key secondary outcomes
Demographic dates, postoperative pain score, need for supplemental analgesics, severity for PONV, times of PONV episodes, use of antiemetics, presence of motor blockade, the sensory block level, postoperative QTc intervals, volume of the study solution, and other adverse events
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
NO
Dynamic allocation
YES
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Medicine |
Interventions/Control_1
Control group: They will receive intraoperative IV droperidol and PCEA without droperidol in combination with fentanyl 4 mcg/mL and ropivacaine 0.06%. Before induction of general anesthesia, an epidural catheter is inserted at the Th9-10, Th10-11, Th11-12, Th12-L1 or L1-2 interspace. General anesthesia is induced with remifentanil, propofol and rocuronium followed by tracheal intubation. Anesthesia is maintained with sevoflurane, remifentanil and fentanyl without nitro oxide. Intraoperative epidural analgesia is achieved with 1, 1.5, 2 % mepivacaine 4-8 mL bolus injection followed by continuous infusion at 5 mL/h. 1.25 mg of droperidol is given after before the start of operation. On initiation of wound closure, the epidural catheter is connected to a PCEA pump (JMS) is set for a first loading dose 8 mL, a bolus dose of 2 mL, with a 10-min lockout interval, and a background infusion 4 mL/h. PCEA is made a dosage adjustment by attending surgeons and continued to at least the third postoperative day. A blinded investigator visits patients repeatedly to assure adequate analgesia, proper equipment function, and stable vital signs. Data collections are made by the anesthesiologist in attendance and a blind investigator at the end of anesthesia, at 1-5h after the completion of surgery (POD0), in the first postoperative morning (POD1M), in the afternoon (POD1A), in the second postoperative morning (POD2M) and in the third postoperative morning (POD3M).
Interventions/Control_2
Droperidol group: They will receive intraoperative IV droperidol and PCEA with droperidol in combination with fentanyl 4 mcg/mL and ropivacaine 0.06%. Before induction of general anesthesia, an epidural catheter is inserted at the Th9-10, Th10-11, Th11-12, Th12-L1 or L1-2 interspace. General anesthesia is induced with remifentanil, propofol and rocuronium followed by tracheal intubation. Anesthesia is maintained with sevoflurane, remifentanil and fentanyl without nitro oxide. Intraoperative epidural analgesia is achieved with 1, 1.5, 2 % mepivacaine 4-8 mL bolus injection followed by continuous infusion at 5 mL/h. 1.25 mg of droperidol is given after before the start of operation. On initiation of wound closure, the epidural catheter is connected to a PCEA pump (JMS) is set for a first loading dose 8 mL, a bolus dose of 2 mL, with a 10-min lockout interval, and a background infusion 4 mL/h. PCEA is made a dosage adjustment by attending surgeons and continued to at least the third postoperative day. A blinded investigator visits patients repeatedly to assure adequate analgesia, proper equipment function, and stable vital signs. Data collections are made by the anesthesiologist in attendance and a blind investigator at the end of anesthesia, at 1-5h after the completion of surgery (POD0), in the first postoperative morning (POD1M), in the afternoon (POD1A), in the second postoperative morning (POD2M) and in the third postoperative morning (POD3M).
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Female
Key inclusion criteria
Written informed consent, ASA physical status 1 or 2 female patients scheduled to undergo gynecological surgeries under combined general-epidural anesthesia.
Key exclusion criteria
Those have known hypersensitivity to any drugs that is part of this study protocol, contraindications to epidural anesthesia, current opioid use, inability to use the PCEA device, alcohol or narcotic dependence, renal or hepatic insufficiency, QT elongation (QTc interval >450 ms) on preoperative electrocardiogram (ECG) assessment, Parkinsonism, demand premedication, a history of operations under combined general-epidural anesthesia, and a history of severe PONV.
Target sample size
150
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Emi Nakajima |
Organization
University of Yamanashi Hospital
Division name
Depatment of Anesthesiology
Zip code
Address
1110,shimokato,Chuo,Yamanashi,409-3898 Japan
TEL
055-273-9690
emis@yamanashi.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Emi Nakajima |
Organization
University of Yamanashi, Faculty of University of Yamanashi Hospital
Division name
Depatment of Anesthesiology
Zip code
Address
1110,shimokato,Chuo,Yamanashi,409-3898 Japan
TEL
055-273-9690
Homepage URL
emis@yamanasi.ac.jp
Sponsor or person
Institute
University of Yamanashi Hospital
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
山梨大学医学部付属病院（山梨県）
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 10 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 07 | Month | 13 | Day |
Date of IRB
Anticipated trial start date
| 2011 | Year | 11 | Month | 01 | Day |
Last follow-up date
| 2013 | Year | 02 | Month | 15 | Day |
Date of closure to data entry
| 2014 | Year | 02 | Month | 15 | Day |
Date trial data considered complete
| 2014 | Year | 03 | Month | 31 | Day |
Date analysis concluded
| 2014 | Year | 07 | Month | 31 | Day |
Other
Other related information
Management information
Registered date
| 2011 | Year | 09 | Month | 26 | Day |
Last modified on
| 2014 | Year | 08 | Month | 22 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007600
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
